Last $75.61 USD
Change Today -3.44 / -4.35%
Volume 481.6K
CLVS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:39 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

clovis oncology inc (CLVS) Snapshot

Open
$78.25
Previous Close
$79.05
Day High
$78.88
Day Low
$74.24
52 Week High
03/6/14 - $93.33
52 Week Low
08/4/14 - $35.33
Market Cap
2.6B
Average Volume 10 Days
490.1K
EPS TTM
$-4.56
Shares Outstanding
34.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLOVIS ONCOLOGY INC (CLVS)

clovis oncology inc (CLVS) Related Businessweek News

No Related Businessweek News Found

clovis oncology inc (CLVS) Details

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and a collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

136 Employees
Last Reported Date: 02/27/15
Founded in 2009

clovis oncology inc (CLVS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $924.5K
Co-Founder, Chief Medical Officer and Executi...
Total Annual Compensation: $635.0K
Co-Founder, Chief Regulatory Officer and Exec...
Total Annual Compensation: $592.3K
Co-Founder, Chief Financial Officer and Execu...
Total Annual Compensation: $592.3K
Senior Vice President of Commercial
Total Annual Compensation: $501.4K
Compensation as of Fiscal Year 2013.

clovis oncology inc (CLVS) Key Developments

Clovis Oncology, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Clovis Oncology, Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported operating loss of $53,890,000 compared to $28,494,000 a year ago. Loss before income taxes was $55,088,000 compared to $29,151,000 a year ago. Net loss was $54,907,000 or $1.62 per basic and diluted share compared to $29,203,000 or $0.92 per basic and diluted share for the fourth quarter of 2013. For the full year, the company reported revenue of $13,625,000. Operating loss was $158,459,000 compared to $83,767,000 a year ago. Loss before income taxes was $157,723,000 compared to $84,480,000 a year ago. Net loss was $160,031,000 or $4.72 per basic and diluted share compared to $84,532,000 or $2.95 per basic and diluted share a year ago.

Clovis Oncology, Inc. to Report Q4, 2014 Results on Feb 25, 2015

Clovis Oncology, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 25, 2015

Clovis Oncology, Inc., Q4 2014 Earnings Call, Feb 25, 2015

Clovis Oncology, Inc., Q4 2014 Earnings Call, Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLVS:US $75.61 USD -3.44

CLVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLVS.
View Industry Companies
 

Industry Analysis

CLVS

Industry Average

Valuation CLVS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 190.5x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 134.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLOVIS ONCOLOGY INC, please visit www.clovisoncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.